NCT00724789 is a clinical trial of ganirelix in Pregnancy, sponsored by Organon and Co.

Who is sponsoring NCT00724789?

NCT00724789 is sponsored by Organon and Co.

What drugs are being tested in NCT00724789?

Interventions in NCT00724789: ganirelix, GnRH agonist.

What condition does NCT00724789 study?

NCT00724789 studies Pregnancy, Neonates.

Is NCT00724789 still recruiting?

NCT00724789 is currently completed. Last updated 1 February 2022.

Last reviewed 2022-02-01 · How we verify

NCT00724789

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Observational Trial to Monitor the Incidence of Congenital Malformations in Infants of Women With an Ongoing Pregnancy After Controlled Ovarian Hyperstimulation Using Puregon® (recFSH)/Orgalutran® (Ganirelix) Followed by IVF/ICSI, or a Long Protocol With a GnRH Agonist as Historical Controls.

Completed Last updated 1 February 2022

What this trial tests

trial testing ganirelix in Pregnancy in 2,066 participants. Completed in 1 November 2005.

Timeline

1 November 2000

Primary endpoint
1 November 2005

1 November 2005

Quick facts

Lead sponsor	Organon and Co
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,066
Start date	1 November 2000
Primary completion	1 November 2005
Estimated completion	1 November 2005

Drugs / interventions tested

ganirelix (GANIRELIX) — full drug profile →
GnRH agonist — full drug profile →

Conditions studied

Pregnancy — all drugs for Pregnancy →
Neonates — all drugs for Neonates →

Sponsor

Organon and Co — full company profile →

Who can join

Adults 18 to 39, female only, with Pregnancy or Neonates. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian hyperstimulation.
Time frame: In both cohorts a follow-up pediatric evaluation was scheduled within 6 months post-partum

Sponsor's own description

The primary purpose of this study is to collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian stimulation with recombinant follicle stimulating hormone /ganirelix followed by in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI), and to compare this incidence with that of a group of women who used a long protocol with a gonadotropin releasing hormone agonist as historical controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pregnancy

Currently open trials in the same condition.

NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07385807 — Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Out · recruiting
NCT07226492 — Cash Transfers to Pregnant Women With HIV · NA · recruiting
NCT07435766 — Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy · NA · recruiting

Other Organon and Co trials

Trials by the same sponsor.

NCT05761444 — Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients · Phase 4 · completed
NCT05789576 — A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Regi · Phase 4 · completed
NCT05680740 — A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis · Phase 4 · completed
NCT05560646 — A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 · Phase 2 · completed
NCT05264506 — Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00724789 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Organon and Co
Last refreshed: 1 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00724789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing